 This phase II trial studies how well nivolumab works in treating patients with nasopharyngeal cancer that has returned after a period of improvement recurrent andor has spread to other parts of the body metastatic. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells. 